Quick Answer
Kairos Pharma, LTD. reported Operating Income of -$5.57 million for fiscal year 2025.
Kairos Pharma, LTD. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$5.57M | -137.8% |
| 2024 | -$2.34M | -36.7% |
| 2023 | -$1.71M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.44M | -274.7% | +1.4% |
| June 30, 2025 | -$1.46M | -555.9% | -15.0% |
| March 31, 2025 | -$1.27M | -341.1% | -230.5% |
| September 30, 2024 | -$383.0K | -33.4% | -72.5% |
| June 30, 2024 | -$222.0K | — | +22.6% |
| March 31, 2024 | -$287.0K | — | +0.0% |
| September 30, 2023 | -$287.0K | — | — |
- Kairos Pharma, LTD. showed a decrease of -137.8% in Operating Income compared to the prior fiscal year.
- Over the 2023–2025 period, Kairos Pharma, LTD.’s operating income has declined by 225.1% (from -$1.71 million to -$5.57 million).
- The most recent figure is from Kairos Pharma, LTD.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: